These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 30859272)

  • 1. Smarter screening for prostate cancer.
    Tan GH; Nason G; Ajib K; Woon DTS; Herrera-Caceres J; Alhunaidi O; Perlis N
    World J Urol; 2019 Jun; 37(6):991-999. PubMed ID: 30859272
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
    Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
    Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinically significant Prostate Cancer diagnosed using a urinary molecular biomarker-based risk score: two case reports.
    Minnee P; Hessels D; Schalken JA; Van Criekinge W
    BMC Urol; 2019 Nov; 19(1):124. PubMed ID: 31783839
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate cancer screening in men aged 50 to 69 years (STHLM3): A prospective population-based diagnostic study. Grönberg H, Adolfsson J, Aly M, Nordström T, Wiklund P, Brandberg Y, Thompson J, Wiklund F, Lindberg J, Clements M, Egevad L, Eklund M.Lancet Oncol. 2015 Dec;16(16):1667-76. [Epub 2015 Nov 10]. doi: 10.1016/S1470-2045(15)00361-7.
    Scott E; Adolfsson J; Aly M; Nordström T; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Clements M; Egevad L; Eklund M
    Urol Oncol; 2017 Mar; 35(3):120. PubMed ID: 28215847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore.
    Verbeek JFM; Bangma CH; Kweldam CF; van der Kwast TH; Kümmerlin IP; van Leenders GJLH; Roobol MJ
    Urol Oncol; 2019 Feb; 37(2):138-144. PubMed ID: 30528698
    [TBL] [Abstract][Full Text] [Related]  

  • 6. On the use of prostate-specific antigen for screening of prostate cancer in European Randomised Study for Screening of Prostate Cancer.
    Bangma CH; van Schaik RH; Blijenberg BG; Roobol MJ; Lilja H; Stenman UH
    Eur J Cancer; 2010 Nov; 46(17):3109-19. PubMed ID: 21047594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive predictive value of prostate biopsy indicated by prostate-specific-antigen-based prostate cancer screening: trends over time in a European randomized trial*.
    Bokhorst LP; Zhu X; Bul M; Bangma CH; Schröder FH; Roobol MJ
    BJU Int; 2012 Dec; 110(11):1654-60. PubMed ID: 23043563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the diagnostic options for prostate cancer.
    French WW; Wallen EM
    Postgrad Med; 2020 Dec; 132(sup4):52-62. PubMed ID: 32900250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [PSA screening and molecular markers].
    Lakes J; Arsov C
    Urologe A; 2019 May; 58(5):486-493. PubMed ID: 30874831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical utility and cost modelling of the phi test to triage referrals into image-based diagnostic services for suspected prostate cancer: the PRIM (Phi to RefIne Mri) study.
    Kim L; Boxall N; George A; Burling K; Acher P; Aning J; McCracken S; Page T; Gnanapragasam VJ
    BMC Med; 2020 Apr; 18(1):95. PubMed ID: 32299423
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Focus on the screening for prostate cancer by PSA].
    Roumeguère T; Van Velthoven R
    Rev Med Brux; 2013 Sep; 34(4):311-9. PubMed ID: 24195246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Stockholm-3 (STHLM3) Model can Improve Prostate Cancer Diagnostics in Men Aged 50-69 yr Compared with Current Prostate Cancer Testing.
    Eklund M; Nordström T; Aly M; Adolfsson J; Wiklund P; Brandberg Y; Thompson J; Wiklund F; Lindberg J; Presti JC; StLezin M; Clements M; Egevad L; Grönberg H
    Eur Urol Focus; 2018 Sep; 4(5):707-710. PubMed ID: 28753803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature.
    Fütterer JJ; Briganti A; De Visschere P; Emberton M; Giannarini G; Kirkham A; Taneja SS; Thoeny H; Villeirs G; Villers A
    Eur Urol; 2015 Dec; 68(6):1045-53. PubMed ID: 25656808
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of Magnetic Resonance Imaging in Prostate Cancer Screening: A Pilot Study Within the Göteborg Randomised Screening Trial.
    Grenabo Bergdahl A; Wilderäng U; Aus G; Carlsson S; Damber JE; Frånlund M; Geterud K; Khatami A; Socratous A; Stranne J; Hellström M; Hugosson J
    Eur Urol; 2016 Oct; 70(4):566-573. PubMed ID: 26724840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improving the Specificity of PSA Screening with Serum and Urine Markers.
    Kearns JT; Lin DW
    Curr Urol Rep; 2018 Aug; 19(10):80. PubMed ID: 30105509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiparametric magnetic resonance imaging of the prostate can improve the predictive value of the urinary prostate cancer antigen 3 test in patients with elevated prostate-specific antigen levels and a previous negative biopsy.
    Sciarra A; Panebianco V; Cattarino S; Busetto GM; De Berardinis E; Ciccariello M; Gentile V; Salciccia S
    BJU Int; 2012 Dec; 110(11):1661-5. PubMed ID: 22564540
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum and urine biomarkers for detecting clinically significant prostate cancer.
    Becerra MF; Atluri VS; Bhattu AS; Punnen S
    Urol Oncol; 2021 Oct; 39(10):686-690. PubMed ID: 32241692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Zinc α2-glycoprotein as a potential novel urine biomarker for the early diagnosis of prostate cancer.
    Katafigiotis I; Tyritzis SI; Stravodimos KG; Alamanis C; Pavlakis K; Vlahou A; Makridakis M; Katafigioti A; Garbis SD; Constantinides CA
    BJU Int; 2012 Dec; 110(11 Pt B):E688-93. PubMed ID: 23020913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement.
    ; Grossman DC; Curry SJ; Owens DK; Bibbins-Domingo K; Caughey AB; Davidson KW; Doubeni CA; Ebell M; Epling JW; Kemper AR; Krist AH; Kubik M; Landefeld CS; Mangione CM; Silverstein M; Simon MA; Siu AL; Tseng CW
    JAMA; 2018 May; 319(18):1901-1913. PubMed ID: 29801017
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.